NCT02111954|Completed
Ga-68-NODAGA-MJ9 Compared to F-18-FCH PET/CT for Prostate Cancer Patients
PET/CT Study of GRP Receptors With Ga-68-NODAGA-MJ9 in Prostate Cancer Compared to F-18-FCH PET / CT
Loading search results
PET/CT Study of GRP Receptors With Ga-68-NODAGA-MJ9 in Prostate Cancer Compared to F-18-FCH PET / CT
Sponsor study identifier
observational
60
1 country
1
Study Start
April 2014
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
October 28, 2016
Actual (reported)Study Completion
October 28, 2016
Actual (reported)Prostate cancer patients for whom a F-18-FCH PET/CT is indicated. Ga-68-NODAGA-MJ9 is a new PET/CT radiotracer aiming at giving complementary information : more precise images and early localisation of recurrence to standard imaging
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
October 28, 2016
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
April 2014
Date type not reportedThis date has not been verified as actual or estimated.
April 9, 2014
Actual (reported)April 11, 2014
Actual (reported)October 28, 2016
Actual (reported)October 28, 2016
Actual (reported)Positivity of the new radiotracer Ga-68-NODAGA-MJ9 compared to the standard radiotracer F-18-FCH
PET images : SUVmax, SUVmean, VOI (mL), SUV41% lesions/ SUVbackground CT images : size lesions measured in 3D (axial, coronal and sagittal), density in Hounsfield Units (HU)
At baseline (after F-18-FCH PET/CT)
1 PET/CT with F-18-FCH + 1 PET/CT with Ga-68-NODAGA-MJ9
Each patient will have two PET/CT
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Patient with proven prostate cancer
Centre Hospitalier Universitaire Vaudois
Lausanne, Canton of Vaud, 1011, Switzerland
Gnesin S, Cicone F, Mitsakis P, Van der Gucht A, Baechler S, Miralbell R, Garibotto V, Zilli T, Prior JO. First in-human radiation dosimetry of the gastrin-releasing peptide (GRP) receptor antagonist 68Ga-NODAGA-MJ9. EJNMMI Res. 2018 Dec 12;8(1):108. doi: 10.1186/s13550-018-0462-9.
John O. Prior, MD, PhD
University of Lausanne Hospitals
60 participants (actual enrollment reported by the registry).
First Submitted
April 9, 2014
First Posted
April 11, 2014
Study Start
April 2014
Date type not reportedThis date has not been verified as actual or estimated.
PET/MRI for Men Being Considered for Radiotherapy for Suspected Prostate Cancer Recurrence Post-Prostatectomy
Contact the study team to confirm eligibility.
Primary Completion
October 28, 2016
Actual (reported)Study Completion
October 28, 2016
Actual (reported)Last Updated
May 23, 2017
Record last verified: 2017-05
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: